High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy

Inclusion Criteria

• •1. Informed consent
• •2. Age: 19-80 years old
• •3. Complete or partial response according to Response Evaluation Criteria In Solid Tumors (RECIST) or Gynecologic Cancer Intergroup criteria in epithelial ovarian cancer, fallopian cancer, or primary peritoneal cancer patients who underwent either surgery or chemotherapy and those who have recurred cancer at least six months after chemotherapy.
• •4. Patients who have received paclitaxel chemotherapy for a minimum of 6 cycles and a maximum of 9 cycles
• •5. Eastern Cooperative Oncology Group performance status 0-2
• •6. Patients with no other concurrent disease affecting overall survival
• •7. Patients with normal hematologic, renal, and liver functions
• •8. Patients who understand the contents of the clinical trial and are capable of participating until the end of the trial